<DOC>
	<DOCNO>NCT02728349</DOCNO>
	<brief_summary>The purpose study : Determining Maximum Tolerated Dose ( MTD ) , Dose-Limiting Toxicity ( DLT ) , pharmacokinetics characteristic , dosage regimen phase II/III Chlorogenic acid injection advance Glioblastoma Patients ;</brief_summary>
	<brief_title>Tolerance Pharmacokinetic Study Chlorogenic Acid Advanced Glioblastoma</brief_title>
	<detailed_description>1 . Investigate tolerance Chlorogenic acid injection human body , determine Maximum Tolerated Dose ( MTD ) Dose-Limiting Toxicity ( DLT ) Chlorogenic acid injection advance Glioblastoma Patients ; 2 . Determine human pharmacokinetics characteristic Chlorogenic acid injection ; 3 . Preliminary observation effectiveness effective dose ; 4 . Provide basis dosage regimen phase II/III .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Patients pathologic or/and FNAC confirmation advance glioblastoma ( WHO , IIIIV grade ) without effective treatment treatment failure ; 2 . Between 18 65 year age , KPS≥40 ; 3 . According RANO ( 2010 ) , parent eligible one follow condition apply : steroid dose increase stable , enhanced tumor lesion increase 25 % ; unenhanced tumor lesion increase progressive tumor , even lesion unmeasurable . 4 . Life expectancy least three ( 3 ) month enrollment ; 5 . Patients sufficient baseline organ function whose laboratory data meet follow criterion enrollment : 1 ) PLT count≥100×10~9/L , 2 ) WLB count≥4.0×10~9/L ≤12×10~9/L , 3 ) Neutrophil granulocyte count≥2.0×10~9/L , 4 ) HGB count≥90g/L , 5 ) Total bilirubin &lt; =1.5 time ULN , 6 ) ALT/AST ≤2.5 time ULN , 7 ) SCr≤1.5 time ULN , 8 ) Normal ECG LVEF ( ≥50 % ) measure echocardiography ; 6.Female patient negative pregnant test , male/female patient reproductive age without pregnancy plan next 12 month ; 7.Volunteered phase 1 trial sign inform consent without protest ; 1 . Patients receive large area radiotherapy （ &gt; 30 % marrow capacity） ; 2 . Without pathologic or/and FNAC confirmation advance glioblastoma ; 3 . Patients primary immunodeficiency diseases； 4 . Patients suffer serious complication , uncontrollable infection , myocardial infarction within past 6 month enrollment , uncontrollable hypertension , thromboembolism etc . ; 5 . Patients receive therapy chemotherapy radical radiotherapy within 4 week enrollment ; 6 . Patients used nitrosoureas drug mitomycin within 6 week tyrosine kinase inhibitor within 2 week enrollment ; 7 . Patients receive therapy major surgery within 4 week biopsy surgery within 2 week enrollment ; 8 . Patients experience grade 2 grade 2 toxicity cause past therapy ; 9 . Patients history drug abuse ; 10 . Uncontrollable psychopaths； 11 . Uncontrollable diabetes； 12 . Pregnant breastfeed woman , patient ( male female ) pregnancy plan ; 13 . Patients receive therapy another investigational drug within 12 week patient still another clinical trial enrollment ; 14 . Known active hepatitis B/hepatitis C , positive HIV/ syphilis antibody ; 15 . Patient need long term treatment cortical hormone immunosuppressive drug visceral organ transplanter ; 16 . Allergic investigational drug ; 17 . Other patient judge ineligible enrollment study investigator ( subinvestigator ) . 18 . Patients receive therapy adrenal steroid hormone within 1 week enrollment receive therapy long period time，except Corticosteroid nasal spray，Inhaled Steroid Topical steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>